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Abstract
This literary review examines some genes and proteins such as presenilin 1
presenilin 2, amyloid precursor protein, and apolipoprotein E, and Tau that are
associated with Alzheimer’s disease. It also delves into four causal hypotheses for
Alzheimer’s disease: the oxidative stress-induced AD cascade hypothesis, the copper-2
hypothesis, the amyloid cascade hypothesis, and the type II diabetes mellitus
hypothesis. It further explains some of the current ways of diagnosing Alzheimer’s
disease and its different forms; symptoms that have been associated with Alzheimer’s
disease; and the different demographics of Alzheimer’s disease. Finally, different
treatments, preventions, risks, and current research for Alzheimer’s disease is
reviewed.
Overall, Alzheimer’s has been shown to affect non-Hispanic white populations
between the ages of 75-85 years old the most (Herbert et al. 2003, Plassman et al.
2007, Herbert et al 2013). Significant contributors to the disease included type II
diabetes, cardiovascular diseases, and diets high in saturated and trans-unsaturated
fats (Luchsinger et al. 2001, Morris et al. 2003, & Elias et al. 2004). A number of studies
have found that a healthy diet that includes a moderate amount of fish, continued
physical exercise, and continued mental exercise may help decrease the effects of
Alzheimer’s disease and dementia (Wang et al. 2006, Feart et al. 2010, &Kivipelto &
Håkansson 2017).

Introduction
Alzheimer’s disease (AD) is the most common form of dementia making up twothirds of all dementia cases (Guttmacher & Collins 2003). There has been a substantial
amount of advancement since the initial description of Alzheimer’s disease in 1906
(Tagarelli et al. 2006). However, it remains difficult to pin-point exact causes; and new
criteria for diagnosis of AD are continually being formed (Serrano-Pozo et al. 2014).
There is also still an extensive debate regarding relationships between autopsy
neuropathological findings and AD correlation (Nelson et al. 2013).
Throughout this literary review I will examine genes and proteins associated with
AD, current causal hypotheses for AD, biochemical changes with AD, symptoms of AD,
and the most current method of diagnosing AD. Continuing forward I will look at the
demographics of AD, possible ways to reduce the risk of developing AD, and current
treatments of AD. Finally, I will delve into some of the current studies taking place today
involving AD diagnosis, treatment, and prevention.
Genes & proteins associated with AD
There are four readily confirmed genes associated with Alzheimer’s disease:
presenilin 1 (PSEN1), presenilin 2 (PSEN2), amyloid precursor protein (APP), and
apolipoprotein E (APOE) (Williamson et al. 2009). The Tau protein is also highly
associated with AD (Kimura 2016). PSEN1 gene provides instructions for the presenilin
1 protein which is a proteolytic subunit of gamma-secretase. PSEN2 gene similarly
provides instructions for the presenilin 2 protein which is another subunit of gammasecretase and has also been linked to mitochondria-dependent apoptosis. The gamma-

secretase enzyme cleaves transmembrane proteins into peptides and is involved with
the cutting of APP into soluble amyloid precursor protein (sAPP) and several versions of
amyloid-beta (Aβ) peptide. sAPP shows growth promoting properties and is perhaps
involved in the differentiation, development, or synaptic function of nerve cells
(Thinakaran & Parent 2004). APP is a single-pass transmembrane protein; its function
is not definitive although it has been shown to have a positive effect on cell health and
growth when overexpressed. APP has also been shown to modulate cell growth,
motility, neurite growth, and cell survival in transiently infected lines (O’Brien & Wong
2011). APOE combines with lipids to form lipoproteins which provide movement of
cholesterol through the vascular system. It has three main alleles: e2, e3, and e4, with
e3 being the most common (Ashford 2004). Tau proteins are associated with the
stabilization and flexibility of microtubules in neurons. They are derived from the
alternative splicing of microtubule-associated protein tau gene (Mandelkow et al. 1995).
It is essential to understand PSEN1, PSEN2, APP, APOE, Tau, and all of their relations
to move forward. I will discuss them and their functions within AD further throughout the
remainder of the paper.
Causal hypotheses
There are many hypotheses that attempt to explain the cause of AD in order to
try to find a possible treatment, prevention, and/or cure for the disease. Following I will
discuss four varying hypotheses: the oxidative stress-induced AD cascade hypothesis,
the copper-2 hypothesis, the amyloid cascade hypothesis, and the type II diabetes
mellitus hypothesis.

The oxidative stress-induced AD cascade hypothesis states that AD patients and
animal models show oxidative damage to their neurons prior to amyloid plaques and
neurofibrillary tangles. Oxidative stress occurs when some of the free radicals used
during aerobic respiration within mitochondria escape and cause alterations on other
macromolecules within a cell (Bonda et al. 2014). These alterations may cause proteins
to become insoluble or aggregate abnormally by promoting protein cross-linkages and
impaired proteolysis (Zhu et al. 2012 & Domenico et al. 2013). Oxidation of
deoxyribonucleic acid/ribonucleic acid may also lead to fragmentation and defects in
essential repair machinery (Nunomura et al. 2012 & Bradley-Whitman et al 2014.) It is
also noted that oxidative stress appears to be selective in AD patients—being found in
areas such as the hippocampus and cortex, but not the cerebellum (Sultana &
Butterfield 2013). This selectivity is predicted to be a result of the higher metabolic
demands seen in neurons with long axons and multiple synapses. This hypothesis does
suffer some shortcomings, however, as it is unable to explain the predictable and
consistent spread of neurodegeneration throughout distinct regions within the brain
(Bonda et al. 2014).
The copper-2 hypothesis proposes that AD is caused from the consumption of
inorganic copper from drinking water traveling through copper piping and copper
containing supplement pills (Brewer 2017). Some evidence in support of this hypothesis
includes the accelerated cognitive decline in those with a high intake of copper and a
high diet of both saturated and trans fats (Morris et al. 2006) and AD being more
prominent after the 20th century in developed countries compared to both
underdeveloped countries and the years prior to the 20th century. The hypothesis

furthers that this increase in AD cases is not due to increased life-spans seen after the
20th century, but because of increased development in living styles. The support for this
argument shows that there is an increased percentage of cases in those diagnosed with
AD in developed countries compared to underdeveloped countries. They further argue
that if AD cases increased due to increased life-span, then AD cases would have been
seen more often or described more often prior to the 20th century in cases where there
were large populations of citizens over the age of 60 years old in France and the US
prior to the 20th century (Brewer 2017).
The amyloid cascade hypothesis predicts that the primary influence of AD
pathology is caused by the accumulation of Aβ in the brain. The other hallmarks of AD
are proposed to be a result from an imbalance in Aβ production and clearance (Hardy &
Selkoe 2002). The hypothesis contends that Aβ accumulation leads directly to a
cascade of synapse loss, plaque deposition, inflammation, hyperphosphorylation, and
finally death of neurons. According to the hypothesis, familial AD is caused by a
mutation in either APP, PSEN1, or PSEN2 genes that cause an accumulation of an
amyloid peptide that has a high tendency to form β-pleated sheets which aggregate into
oligomers and plaques. It furthers that sporadic AD develops when an individual’s
personal history expedites normal age-dependent Aβ accumulation. In either case, Aβ
accumulation triggers an immune response which in turn stimulates more Aβ production
(Herrup 2011).
The type II diabetes mellitus hypothesis predicts that AD pathology is aggravated
and perhaps even induced by aberrant insulin signaling. This hypothesis is grounded on
the fact that neurofibrillary tangles are caused from the accumulation of aggregated

Tau; Tau aggregations are produced from the hyperphosphorylation of Tau; and that the
hyperphosphorylation of Tau can be caused by the abnormal activation of glycogen
synthase kinase 3β which can be induced by insulin deficiency/ resistance seen in those
with diabetes mellitus (Kimura 2016). Type II diabetes mellitus may also induce Aβ
accumulation through a change in the pathway of the intracellular transportation via
endocytosis of APP and beta site amyloid precursor protein cleaving enzyme 1(Koh et
al. 2005 & Okabayashi et al. 2015). Evidence of Aβ pathology induced by type II
diabetes has been shown in nonhuman primate brains (Okabayashi et al. 2015). Some
recent studies have also shown improvement in the cognition of those with AD with use
of intranasal insulin (Craft et al. 2012 & Claxton et al. 2015).
Diagnosis, biochemical changes, & symptoms
Mild cognitive impairment (MCI) is an initial diagnosis that can lead to the
development of AD. MCI can be seen as a change in cognition from baseline. In order
to be diagnosed with MCI, one most show decline in one or more cognitive domains,
including, yet not limited to: memory, executive function, attention, language, and
visuospatial skills—with episodic memory being most common in those that develop
AD. Patients must be able to perform functional tasks independently although they may
be less efficient, slower, or make more errors performing these functional tasks in order
to receive diagnosis of MCI. The patient’s cognitive changes should also be mild
enough that there is no significant impairment during social or occupational functioning.
Finally, vascular, traumatic, and medical issues that could account for cognitive decline
should be ruled out. Otherwise, the patient has the potential for being diagnosed with
dementia. In order for MCI to be strongly diagnosed as MCI due to AD, there should be

an autosomal dominant mutation in APP, PSEN1, or PSEN2; or the patient should be
APOE e4 positive (Albert et al. 2011).
AD disease, itself, can be diagnosed with evidence of Aβ peptide plaque buildup, tau neurofibrillary tangles, or neural injury (Albert et al. 2011). Evidence of Aβ
peptide plaque build-up can be confirmed with measurements of low amyloid-beta42
levels in the cerebrospinal fluid (Blennow & Hampel 2003, Selkoe 2005, Shaw et al.
2009) and positive Pittsburgh Compound-B binding measurements via positronemission tomography (PET) (Fagan et al. 2006). Elevated cerebrospinal fluid
measurements of tau or phosphorylated-tau provide evidence of both tau neurofibrillary
tangles and neural injury (Blennow & Hampel 2003, Selkoe 2005, Shaw et al. 2009).
Other measurements of neural injury include brain atrophy and hypometabolism or
hypoperfusion measured using magnetic resonance imaging (MRI), PET, and singlephoton emission computed tomography imaging (Atiya et al. 2003, Jagust 2006). Other
biochemical changes that can be accompanied with AD include cell death, synaptic
damage, oxidative stress, or inflammation. Patient’s with positive amyloid-beta
biomarker and a positive biomarker of neuronal injury have a high likelihood of being
diagnosed with/developing AD. Patient’s with only one or the other have an intermediate
likelihood of being diagnosed with/developing AD (Albert et al. 2011).
Generally, there are two accepted forms of AD. The first is early onset
Alzheimer’s disease which occurs before the age of 60-65; and the second being late
onset Alzheimer’s disease which occurs after age 60-65 and is considered the
predominant form of AD (Bertram & Tanzi 2005). Aside from these two forms, there are
three more categories of AD diagnosis, including autosomal dominant, familial, and

sporadic cases. To be diagnosed with autosomal dominant AD, there must be at least
three individuals in two or more generations of a family diagnosed with AD with two of
the three being first-degree relatives of the third. Autosomal dominant AD represents
<5% of AD cases. Familial AD involves more than one individual being diagnosed with
AD and those diagnosed being third degree relatives or closer. This type of AD
represents 15-25% of all cases. Finally, sporadic AD involves an isolated case in a
family or cases with more than three degrees of relationship between them. This
(Goldman et al. 2011).
General symptoms given by the Alzheimer’s Association of AD include memory
loss that disrupts daily functional task, difficulties with planning or problem solving,
difficulty completing familiar functional task, confusion of time or location, vision
problems, problems with speech and comprehension, losing items, decreased decision
making skills, withdrawal from social activities, and changes in mood and personality
(alz.org 2017). However, findings show that the olfactory, visual, auditory, and motor
systems are all affected by AD pathology (Table 1). Some of these symptoms include
impaired odor identification, concomitant eye diseases, speech perception impairments,
hearing loss, and various motor impairments. On their own these effects can seem
coincidental to aging; however, these effects along with positive APP, PSEN1, PSEN2,
or APOE findings may help diagnose the potential for Alzheimer’s prior to any cognitive
impairment (Albers et al. 2015).

Demographics of Alzheimer’s
Overall, the numbers of people affected by AD are shown to be growing. In 2000,
4.5 million were reported to have AD in the US with 7% between the ages of 65-74
years old (y.o.), 53% between 75-84 y.o., and 40% being over 85 y.o (Herbert et al.
2003). In 2010, 4.7 million were reported to have AD in the US with 14% between the
ages of 65-74 y.o., 49% between 75-84 y.o., and 37% being over 85 y.o (Herbert et al.
2013) (Figure 1). It was estimated in 2012, that there were 24 million people worldwide
with AD and it was predicted that this number will double every 20 years (Mayeux &
Stern 2012).
When reviewing AD occurrence and differences in both men and women, some
studies have noted AD occurrence to be significantly higher in women compared to
men. It was also noted that these differences may be because women on average live
longer than men (Plassman et al. 2007, Mielke et al. 2014, Podcasy & Epperson 2016).
Women have also been shown to be diagnosed earlier and their symptoms to progress
faster; but men with AD are shown to live shorter lives than women with AD (Todd et al
2013, Podcasy & Epperson 2016) Risk factors that contribute to AD such as smoking,
coronary artery disease, and brain injury with loss of consciousness are more common
among men. Diabetes, obesity, and hypertension are also more common among men,
but pose a higher risk when in women for AD. Greater life-long exposure to estrogen
may also increase risk of AD contributing to women’s diagnosis of AD (Podcasy &
Epperson 2016).

Very few studies included demographics on race/ethnicity as most studies were
largely of those who consider themselves to be Caucasian. One study, however, shows
AD population to be made up of 82.1% non-Hispanic white people, 12.9% non-Hispanic
black people, and 5% to be Hispanic people (Plassman et al. 2007).
Risk reduction & risk contribution
There are many possible associations between risk reduction, risk contribution,
diseases, and life habits (Table 2). For example, populations with prototypical AD
manifestations have been shown to present with cerebrovascular disease more often
than not suggesting that the presence of a cerebrovascular disease may contribute to
AD (Schneider & Bennett 2010). Mid-life hypertension has also been considered a
contributor to late onset dementia (Yamada et al. 2003, Elias et al. 2004, Whitmer et al
2005). Risk of AD has been shown to approximately double with presence of type II
diabetes (Luchsinger et al. 2001, Farris et al. 2003, Luchsinger et al. 2004). It has also
been suggested that Diabetes directly affects Aβ accumulation in the brain due to
hyperinsulinemia competing for the insulin-degrading enzyme thereby disrupting Aβ
clearance (Farris et al 2003). Several studies have been able to link high and low
weights, weight gain, and weight loss to increasing the risk of AD (Gustafson et al.
2003, Brubacher et al. 2004, Buchman et al. 2005, Stewart et al. 2005, Atti et al. 2008).
After traumatic brain injury, Aβ deposition (Iwata et al. 2002) and intraneuronal tau
pathology—which both are associated with AD—are increased (Smith et al. 2003). Poor
life habits such as high consumption of saturated fats (when compared to low
consumption of saturated fats) can double the incident risk of AD; while transunsaturated fats consumption triples incident risk of AD (Morris et al. 2003).

On the other hand, a lower risk of dementia is seen in those with higher
education (Roe et al. 2008). Good life habits such as the consumption of N-6
polyunsaturated fats and monounsaturated fats (Morris et al. 2003) and weekly
consumption of fish along with regular consumption of omega-3 rich oils have also been
shown to reduce incident risk of AD (Barberger-Gateau et al. 2007). Mediterranean
diets have been associated with slower cognitive decline and reduced risks of AD
(Scarmeas et al. 2006, Feart et al. 2010). Furthermore, increased physical exercise has
been shown to serve a beneficial role in the reduction of AD risk (Podewils et al. 2005,
Larson et al. 2006, Wang et al. 2006).
Treatment & prevention strategies
There are few treatment options when it comes to AD (Table 3). There are a few
of the common AD symptoms along with the current treatment strategies for them, such
as the following:
1) The nucleus basalis of Meynert is a large source of cholinergic innervation of
the cerebral cortex and also an area that shows greater than 70 percent degeneration in
patients with AD (Whitehouse 2006). Successful therapy has been shown to slow the
progression of AD with acetylcholinesterase inhibitors such as donepezil, galantamine,
and rivastigmine that prevent 2 months per year of decline in AD patients (Trinh et al.
2003).
2) In the brains of AD patients, glutamine synthetase is oxidized leading to
excess glutamate which excessively activates N-methyl-D-aspartate (NMDA) receptors

causing neuronal degeneration. Significant reduction in cognitive decline in moderateto-severe AD has been shown with the use of memantine (Reisberg et al. 2003).
3) A variety of antidepressant medications can be used to treat symptoms of AD
such as agitation. Some of these medications include citalopram, fluoxetine, paroxetine,
and sertraline.(Cipriani et al. 2012, Peters et al. 2016) Two benzodiazepines (lorazepam
and oxazepam) are generally used in the treatment of verbal disruptive behavior and
resistance in AD patients (Defrancesco et al. 2015). Finally, severe agitation,
aggression, and psychosis can be treated with antipsychotics such as aripiprazole,
clozapine, haloperidol, olanzapine, and quetiapine although this can lead to increased
risk of cerebrovascular events and death (Herrmann & Gauthier 2008).
One prevention strategy is the consumption of Mediterranean diet which consists
of a high intake of vegetables, legumes, fruits, and cereals; high intake of unsaturated
fatty acids and low intake of saturated fatty acids; moderately high intake of fish; low
intake of dairy products; low intake of meat; and a moderate amount of wine. This diet
has been shown to lower mortality in AD and overall risk of AD (Scarmeas et al. 2006).
A more recent clinical trial known as the Finnish Geriatric Intervention Study to
Prevent Cognitive Impairment and Disability (FINGER) has also proposed a prevention
strategy based on evidence from their clinical trial involving nutritional guidance,
physical exercise, and cognitive training. The diet promoted fruits, vegetables, whole
grains, rapeseed oil, and a fish meal twice a week; meanwhile, it restricted trans-fat,
refined sugars, and alcohol. The physical exercises were gradually increased from 30
minutes of muscle-strength training, aerobic exercise, and postural balance twice a

week to 60 minutes two to three times a week. Finally, the cognitive training included
tasks to improve executive function, memory improvement, and mental speed. Overall,
the clinical trials showed significant evidence that a good diet and physical/mental
exercise can help to improve a person cognitive function (Kivipelto & Håkansson 2017).
Current Research
AD research is a continuous process. Some of the new trials that are currently
being conducted involve: the treatment of cognitively normal individuals with geneticbased risk of developing AD (API-ADAD and API_APOE4 Treatment Trial); the
monitoring of subjects and families with Autosomal-Dominant AD (DIAN-TU); testing of
solanezumab effectiveness on the prevention of sporadic AD in cognitively normal
adults with high levels of amyloid in the brain (A4 Trial); and the use of pioglitazone
(normally used for diabetes mellitus) on cognitively normal adults who are positive for
the translocase of outer mitochondrial membrane 40 homolog gene (TOMM40) and
APOE e4 (TOMMORROW Trial) (Hsu & Marshall 2017).
One recent study involving therapeutic strategies using synthetic peptides or
monoclonal antibodies to decrease Aβ build up in the brain is still ongoing with high
expectations for clinical trials, but safety and difficult adverse effects during active
immunotherapy using the synthetic peptide cause need for concern and obvious
drawbacks. Passive immunotherapy uses monoclonal antibodies with fewer problems
arising in comparison (Barrera-Ocampo & Lopera 2016).
Another recent study investigates the uses of repeated MRI-guided ultrasound
treatments for a noninvasive, temporary, and localized opening of the blood brain

barrier (BBB) to improve drug delivery. This method shows an improvement in the
spatial memory of AD transgenic mice and could potentially lead to a decrease in
plaque build-up and increased neural plasticity (Burgess et al. 2014).
A broad study involving the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
is working toward characterizing clinical, genetic, imaging, and biochemical biomarkers
of AD. They also are working on the development of optimized and standard methods
for AD research that can be used to make large shared databases that could increase
research advancements. Their hope is to identify a combination of biomarkers that will
lead to a more accurate and early diagnosis of AD (Weiner et al. 2013).
Discussion
Alzheimer’s disease remains a continuous topic of research although it is
probable that the subject may shift from prevention of the disease to early detection and
treatment similarly to cancer research (Hsu & Marshall 2017). Most causes of the
disease remain unknown as it is unclear whether many of the hall mark features are the
cause of the disease or caused by it. Further investigation is therefore needed into the
etiology of the disease.
Prevention research could be furthered with potential studies on daily mental
exercises in the prevention of Alzheimer’s Disease. Mental exercises could include
continued reading, brain games, or recreational educational classes among others.
Forms of treatment research could be developed looking at the aspects of an
Alzheimer’s patient’s living situation with the question involving the difference in

cognitive decline in those living with family, those with assisted living, and those living in
geriatric homes.
With the numbers of those with Alzheimer’s continuously rising and the average
person living on to an older age it is pertinent to continue on with Alzheimer’s disease
and other dementia research (Raftery et al. 2014).

Tables and Figures
Table 1.
AD pathology presence in cognitively normal adults, AD patients, and
transgenic mice.
System

Pathology
presence

Pathology
symptoms

Olfactory
System

Peripheral and
central olfactory
neural network

Impaired odor
identification

Visual
System

Peripheral and
central pathways
of the visual
neural system;
visual
association
cortical areas
Central area of
the auditory
neural pathway

Concomitant
eye diseases,
some visual
functions
selectively
impaired in
subgroups
Impairments
in speech
perception
and hearing
loss

Cognitively
Normal
Adults
Presence
Some show
impaired odor
identification
associated
with AD
pathology
presence
Some show
AD pathology
in visual
association
cortical areas

AD Patients
Presence

Most show
impaired odor
identification
associated with
AD pathology
presence

Transgenic
mice
overexpressing
Aβ, tau, or APP
AD pathology
strongly
correlates with
olfactory
perceptual
impairments

Most show AD
AD pathology in
pathology in
retina is
peripheral and
associated with
central
structural and
pathways of the functional
visual neural
disturbances
system
Auditory
Hearing loss is Hearing loss
AD pathology in
System
highly
and central
primary auditory
prevalent in
auditory
cortex
older adults,
dysfunction are
associated with
speech
associated with
changes in
perception
high risk of
auditory evoked
impairments
dementia
responses
are common
conversion
as well
within 5-10
years
Motor
Motor neurons of Various motor Motor
Hyperexcitability AD pathology is
System
the pyramidal
impairments
impairment is
in the primary
associated with
motor pathways
highly
motor cortex, a significant motor
and
prevalent in
substantial
neuron
extrapyramidal
older adults;
amount
impairments at
motor pathways
hypoexcitability experience
the cellular and
in the primary
pyramidal and
behavioral
motor cortex
extrapyramidal
levels
motor
impairments
*Table 1 consolidates the effects of AD pathology on the different sensory and motor systems and the
overall prevalence in cognitively normal adults, AD patients, and transgenic mice. All findings are from a
2015 author manuscript by Albers et al.

Table 2.
Factors contributing to or reducing incidence of Alzheimer’s
disease
Factor
Higher Education
Type II Diabetes

Effect on incident of
AD
Reduces risk
Doubles risk

Mid-life hypertension

Contributes to risk

Cerebrovascular
disease
Weight abnormalities
(high, low, loss, or gain)

Contributes to risk

Traumatic brain injury
High consumption of
saturated fats
Trans-unsaturated fats
consumption
N-6 polyunsaturated
fats and
monounsaturated fats
Fish and/or omega-3
consumption
Mediterranean diet
Physical exercise

Contributes to risk
Doubles risk

(Roe et al. 2008)
(Luchsinger et al. 2001,
Farris et al. 2003,
Luchsinger et al. 2004)
(Yamada et al. 2003,
Elias et al. 2004,
Whitmer et al 2005)
(Schneider & Bennett
2010)
(Gustafson et al. 2003,
Brubacher et al. 2004,
Buchman et al. 2005,
Stewart et al. 2005, Atti
et al. 2008)
(Smith et al. 2003)
(Morris et al. 2003)

Triples risk

(Morris et al. 2003)

Reduces risk

(Morris et al. 2003)

Contributes to risk

(Barberger-Gateau et al.
2007)
Reduction in risk
(Feart et al. 2010)
Possible reduction in
(Podewils et al. 2005,
risk
Larson et al. 2006,
Wang et al. 2006)
*Table 2 examines different factors that involve diseases, injuries, or life choices and how they affect the
risk of developing AD.

Reduces risk

Source

Table 3.
AD Medications, their functions, success, and side effects
Area of
interest(AOI
)

Function of
AOI

Function of
Medicine/Medication
s

Nucleus
basalis of
Meynert

Cholinergic
innervation of
the cerebral
cortex

Acetylcholinesterase
inhibitors: donepezil,
galantamine, and
rivastigmine

Glutamate in
Cortical and
hippocampal
neurons

Principle
excitatory
neurotransmitte
r

Glutamate gated
NMDA channel
blocker: memantine

Seroronin
reuptake

Can cause
agitation

Gammaaminobutyric
acid-A
(GABA)
receptor in
brain
Dopamine
receptors

Inhibits activity
of neurons

Selective serotonin
reuptake inhibitor:
citalopram, fluoxetine,
paroxetine, and
sertraline
GABA channel
opener: lorazepam
and oxazepam

Receptors of
dopamine

Dopamine receptor
blocker: aripiprazole,
clozapine, haloperidol,
olanzapine, and
quetiapine

Success
of
Medicatio
n
Prevention
of 2
months per
year of
decline in
AD
patients
Significant
reduction
of cognitive
decline in
AD
patients
Can
decrease
agitation in
AD
patients
Can
decrease
verbally
disruptive
behavior

Side effects

Source

Facial
flushing,
dyspepsia,
nausea,
vomiting, and
diarrhea

(Trinh et al.
2003)

Dizziness,
and low
frequencies
of confusion
and
hallucination
s
Drowsiness,
nausea, dry
mouth,
insomnia,
diarrhea
Drowsiness,
confusion,
dizziness,
blurred
vision,
weakness
Dry mouth,
blurred
vision,
flushing, and
constipation

(Reisberg et
al. 2003)

(Cipriani et
al. 2012,
Peters et al.
2016)
(Defrancesc
o et al.
2015).

Can
(Herrmann &
decrease
Gauthier
severe
2008)
agitation,
aggression
, and
psychosis
in AD
patients
*Table 3 examines different treatable symptoms of AD, the medications used to treat the symptoms, the
mechanism by which the medication works, the outcomes of the medication use, and possible side
effects from the medications.

Age Demographics of Alzheimer's Disease
Percent of AD population

60
50
40

Year

30

2000
2010

20
10
0
65-74 y.o.

75-85 y.o.

85+ y.o.

Age of AD population

Figure 1. Age demographics of Alzheimer’s disease population in the year 2000 which represents 4.5
million people (Herbert et al. 2003) and the year 2010 which represents 4.7 million people diagnosed with
AD (Herbert et al. 2013).
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